Clifford Chance advises MicroPort Scientific Corporation on US$150 million convertible loan facility and US$300 million credit support
19 June 2024
- Vicky Ma, David Tsai, Anthony Chan, Jia Yin Leong, Jitr Vilaivongse, Florence Yu, Timothy Nip, Kenneth Ip, Xavier Chan, , , Rocky Mui, Andre Da Roza, Matthew Wan
- Hong Kong, Shanghai
Clifford Chance advises MicroPort Scientific Corporation on US$150 million convertible loan facility and US$300 million credit support
Global law firm Clifford Chance has advised MicroPort Scientific Corporation, a global medical devices company listed on the Hong Kong Stock Exchange (HKEX), as borrower's counsel in connection with a US$150 million convertible loan facility and a US$300 million credit support provided by financial institutions. Under the convertible loan agreement, the lenders will obtain certain rights to convert their loan participations into HKEX-listed shares of MicroPort Scientific Corporation.
Partners Vicky Ma and David Tsai co-led the matter, with support from cross-practice lawyers across Hong Kong and Shanghai. The team comprised:
- Banking: Senior associate Anthony Chan, registered foreign lawyers Jia Yin Leong and Jitr Vilaivongse, associates Florence Yu and Timothy Nip and trainee solicitor Jonathan Ling;
- Debt Capital Markets: Senior associate Kenneth Ip and associate Xavier Chan;
- Equity Capital Markets: Partner Christine Xu and counsel Samson Chan;
- Asset Management & Financial Regulatory: Partner Rocky Mui, counsel Andre Da Roza and senior associate Matthew Wan.
Vicky Ma commented on the deal, "The success of this transaction demonstrates our ability to advise clients on complex multidisciplinary matters seamlessly across our banking, debt and equity capital markets and financial regulatory practices. Notably, the convertible loan facility constitutes a connected transaction under the Hong Kong listing rules, so various disclosures and corporate approval requirements needed to be addressed."
David Tsai added, "This transaction underscores a growing trend among Hong Kong-listed companies to strategically refinance their existing debt obligations. Amidst fluctuating market conditions, these entities are increasingly leveraging convertible loan facilities and bank loans to optimise their capital structures. This approach not only provides them with the flexibility to manage their cash flows more efficiently but also offers lenders the opportunity for equity participation through conversion rights."
Clifford Chance has an extensive track record of advising on complex debt-related matters globally, such as advising on Weimob's convertible bonds buyback, issuance of new bonds and new shares placement, as well as MicroPort's convertible bond issuance in 2023.
高伟绅为微创医疗的1.5亿美元可转换贷款和3亿美元贷款授信交易提供法律服务
国际领先律师事务所高伟绅助力微创医疗科学有限公司(“微创医疗”)举借1.5亿美元的可转换贷款和3亿美元金融机构贷款授信,在此次交易中为借款人微创医疗提供法律服务。微创医疗是一家在香港联交所上市的跨国医疗器械企业。根据可转换贷款协议,贷款人有权将贷款份额转换为微创医疗在香港联交所上市的股份。
高伟绅合伙人马颖琪律师和蔡重阳律师共同领导了本次交易,並由高伟绅香港办公室和上海办公室多个业务团队的律师提供支持。法律服务团队的成员包括:
- 银行业务:陈国栋、梁嘉茵、 Jitr Vilaivongse、余巧扬、 聂智峰、 凌家俊
- 债务资本市场:叶家进、陈嘉胜
- 股权资本市场:合伙人许文嘉、陈澍森
- 资产管理与金融监管:合伙人梅家豪、 罗键韬、 温永年
马颖琪律师表示:本交易的成功展现了高伟绅的银行业务、债务资本市场、股权资本市场以及金融监管业务团队在复杂交易中协作,为客户提供无缝衔接法律服务的卓越能力。值得一提的是,由于本次可转换贷款构成香港上市规则下的关连交易,因此需要处理众多披露和公司审批要求。
蔡重阳律师补充:本交易显示香港上市公司对现有债务进行战略性再融资的市场趋势。在市场波动的情况下,企业更多地利用可转换贷款和银行贷款优化资本结构。这不但使得企业能够更加灵活、有效地管理现金流,同时也为贷款人提供了通过债转股参股企业的机会。
高伟绅拥有在全球范围内为复杂债务交易提供法律服务的出色业绩,包括为微盟回购可转换债券、发行新债券和新股配售提供法律服务以及微创医疗2023年的可转换债券发行提供法律服务。